KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Net Cash Flow (2016 - 2025)

Sarepta Therapeutics has reported Net Cash Flow over the past 15 years, most recently at $188.2 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $188.2 million for Q4 2025, down 79.21% from a year ago — trailing twelve months through Dec 2025 was -$304.2 million (down 145.09% YoY), and the annual figure for FY2025 was -$304.2 million, down 145.09%.
  • Net Cash Flow for Q4 2025 was $188.2 million at Sarepta Therapeutics, up from $100.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for SRPT hit a ceiling of $905.2 million in Q4 2024 and a floor of -$882.0 million in Q1 2022.
  • Median Net Cash Flow over the past 5 years was -$32.2 million (2021), compared with a mean of -$34.9 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 1714.55% in 2021 and later plummeted 75526.58% in 2025.
  • Sarepta Therapeutics' Net Cash Flow stood at $517.3 million in 2021, then tumbled by 113.89% to -$71.8 million in 2022, then tumbled by 62.95% to -$117.1 million in 2023, then skyrocketed by 873.16% to $905.2 million in 2024, then plummeted by 79.21% to $188.2 million in 2025.
  • The last three reported values for Net Cash Flow were $188.2 million (Q4 2025), $100.0 million (Q3 2025), and $269.7 million (Q2 2025) per Business Quant data.